Press coverage about BioScrip (NASDAQ:BIOS) has been trending somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioScrip earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.8983752520856 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

BioScrip (NASDAQ BIOS) traded up 1.68% during midday trading on Thursday, reaching $3.03. The company had a trading volume of 1,505,135 shares. The stock’s market capitalization is $386.25 million. The firm’s 50 day moving average is $2.89 and its 200 day moving average is $2.14. BioScrip has a 1-year low of $0.98 and a 1-year high of $3.43.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The business had revenue of $218.11 million for the quarter, compared to the consensus estimate of $220.05 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The company’s revenue for the quarter was down 6.2% compared to the same quarter last year. On average, equities analysts anticipate that BioScrip will post ($0.55) EPS for the current fiscal year.

Several equities research analysts recently issued reports on BIOS shares. Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Jefferies Group LLC reiterated a “buy” rating and issued a $4.00 price objective (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. ValuEngine cut BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub cut BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Finally, SunTrust Banks, Inc. upgraded BioScrip from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $3.25 to $3.75 in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $3.75.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/31/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-bioscrip-bios-stock-price.html.

In other BioScrip news, Director Coliseum Capital Management, L sold 886,478 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $3.08, for a total transaction of $2,730,352.24. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.80% of the company’s stock.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Insider Buying and Selling by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.